Hims & Hers Health (NYSE:HIMS) Stock: Insider Soleil Boughton Sells 3,461 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 3,461 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $29.06, for a total value of $100,576.66. Following the transaction, the insider directly owned 297,348 shares in the company, valued at approximately $8,640,932.88. The trade was a 1.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, September 30th, Soleil Boughton sold 3,461 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.17, for a total transaction of $100,957.37.
• On Wednesday, September 16th, Soleil Boughton sold 6,236 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.86, for a total transaction of $173,734.96.
• On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.33, for a total value of $97,965.14.
• On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.55, for a total value of $691,808.05.

Hims & Hers Health Stock Performance

Shares of HIMS traded down $1.31 on Friday, reaching $28.07. 10,994,953 shares of the company’s stock traded hands, compared to its average volume of 10,819,372. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. The stock has a market cap of $6.55 billion, a PE ratio of -44.56 and a beta of 2.44. The stock’s 50 day simple moving average is $29.25 and its two-hundred day simple moving average is $28.73. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $57.45.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The business had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%. The business’s revenue was up 38.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.17 earnings per share. On average, analysts forecast that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on HIMS. Wall Street Zen upgraded shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Needham & Company LLC lifted their price objective on shares of Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Weiss Ratings reiterated a “sell (d)” rating on shares of Hims & Hers Health in a research note on Friday, August 7th. TD Cowen boosted their target price on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a research note on Tuesday, August 11th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Hims & Hers Health in a research report on Friday, September 11th. They set a “neutral” rating and a $32.00 target price for the company. Three research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and an average price target of $32.43.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Potential peptide-market opportunity supports the stock. Shares rebounded from a recent slump after reports that the Trump administration and the Department of Health and Human Services are reviewing a plan that could improve access to compounded peptides, potentially opening a market estimated at $2.2 billion. Hims & Hers rises as HHS moves ahead with plan for compounding peptides
• Positive Sentiment: International expansion adds a growth catalyst. Hims & Hers launched its “Hers” women’s-health platform in Australia following its $1.15 billion Eucalyptus acquisition. The rollout expands the company’s reach in weight management, hormonal health and hair regrowth and could support longer-term international revenue growth. Hims & Hers launches Hers in Australia
• Neutral Sentiment: Insider selling provides limited signal. Insider Soleil Boughton sold 3,461 shares for approximately $100,577 under a pre-arranged Rule 10b5-1 trading plan, reducing her holdings by about 1.15%. Because the sale was scheduled in advance and she retains a substantial position, it is not necessarily a strong indicator of management’s current outlook. Hims & Hers insider stock sale
• Neutral Sentiment: Investor attention is elevated. Zacks reported increased interest in HIMS, but the article did not identify a new fundamental change in earnings, guidance or valuation. The heightened attention may increase volatility as investors monitor the legal and regulatory developments. Zacks Hims & Hers investor attention report
• Negative Sentiment: Class-action litigation is the dominant overhang. Multiple law firms publicized the same federal securities lawsuit against Hims & Hers and certain executives. The case follows an FTC complaint alleging serious business misconduct. Investors who bought shares between August 4, 2025, and July 29, 2026, have until November 2, 2026, to seek lead-plaintiff status. The litigation could increase legal expenses, reputational damage and potential liabilities. Kaplan Fox Hims & Hers class-action notice

Institutional Investors Weigh In On Hims & Hers Health

Several large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its holdings in Hims & Hers Health by 194.4% during the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after purchasing an additional 2,877,550 shares during the last quarter. State of Michigan Retirement System increased its stake in shares of Hims & Hers Health by 13.7% in the first quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company’s stock worth $48,549,000 after purchasing an additional 280,900 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Hims & Hers Health in the second quarter valued at approximately $46,220,000. Bienville Capital Management LLC bought a new stake in shares of Hims & Hers Health in the second quarter valued at approximately $27,242,000. Finally, Principal Financial Group Inc. raised its position in shares of Hims & Hers Health by 97.3% in the first quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company’s stock valued at $26,620,000 after purchasing an additional 632,282 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.